Three women scientists speak out against cyberbullying

Three women scientists speak out against cyberbullying

Representative image. Credit: Pixabay Photo

Three woman scientists who have spoken to the press about the merits of the anti-malarial drug hydroxychloroquine for treating Covid-19 spoke out this week against cyber-bullying including death threats targeting female colleagues.

"Women may be more prone than men to cyberbullying, which aims to denigrate their probity and scientific competence," they wrote in a letter published in The Lancet on Wednesday.

They referenced scientific articles reporting "receipt of death threats and cyber harassment in Brazil, France and Switzerland after publication of studies that did not demonstrate clinical efficacy" for hydroxychloroquine.

"We fully support our colleagues and feel concerned by what they report, having been victims ourselves... to varying degrees of threats of all kinds, including violent defamatory statements, stalking and misogynistic and gender-oriented attacks," they wrote.

The authors are Caroline Samer, a Swiss pharmacologist, and infectious diseases specialists Alexandra Calmy and Karine Lacombe, of Switzerland and France respectively.

"These attacks were exclusively linked to public interventions in the media, in which we attempted to rationally explain the current state of knowledge on the effectiveness and safety of hydroxychloroquine in the treatment and prevention of Covid-19," they wrote.

"All threats directed at researchers and clinicians must be clearly and unanimously rejected by the scientific community," they said.

The drug, the subject of heated debate especially in France where it has been championed by Marseille-based medical professor Didier Raoult, has long been used to treat malaria, rheumatoid arthritis and lupus.

In June the British-led Recovery trial team said that hydroxychloroquine does nothing to reduce coronavirus mortality, a finding corroborated by the World Health Organization.

Get a round-up of the day's top stories in your inbox

Check out all newsletters

Get a round-up of the day's top stories in your inbox